DGAP-News: Integra LifeSciences Holdings Corporation press release
(firmenpresse) - Integra LifeSciences Holdings Corp.
25.10.2012 09:00
---------------------------------------------------------------------------
Integra LifeSciences Features New MAYFIELD(R) Composite Series Cranial
Stabilization Products at the Congress of European Association of Neurosurgical
Societies
PLAINSBORO, N.J., 2012-10-25 09:00 CEST (GLOBE NEWSWIRE) -- Integra
LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it is
featuring its new MAYFIELD(r) Composite Series Cranial Stabilization products at
the Congress of European Association of Neurosurgical Societies EANS, October
23rd - 27th, 2012, in Bratislava, Slovakia. The MAYFIELD(r) Composite Series
products provide rigid skeletal fixation of a patient's skull during many
standard neurological procedures. Included in these products is a new
MAYFIELD(r) Skull Clamp that has received 510(k) clearance from the United States
Food and Drug Administration (FDA) and CE Mark in the European Union.
The Composite Series products are ideal for standard neurological procedures,
including craniotomies, biopsies, and any procedures where rigid skeletal
fixation is required but intra-operative imaging modalities are not used. The
new products have been engineered using hybrid composite materials for more
durability, rigidity and endurance, especially with regards to the emerging
emphasis on decontamination of the products for the safety of both the patient
and the hospital staff. The time-tested design of the new base unit and the
skull clamp has been engineered with materials and finishes that can withstand
the high temperatures and harsh chemicals required for decontamination. They
can also withstand the protocol for decontamination of highly infectious
diseases as outlined in the World Health Organization (WHO) Infection Control
Guidelines for Transmissible Spongiform Encephalopathies (Switzerland, March
1999) and most of European State Members' requirements.
'We're very pleased that the new MAYFIELD(r) Composite Series products are
available in Europe, Middle East and Africa and will continue to provide our
trusted Mayfield solutions in the cranial stabilization market,' said Thierry
Bordenave, Vice President of Sales&Marketing, Neurosurgery, EMEA.
The Composite Series products include a new MAYFIELD(r) Skull Clamp, along with a
more robust MAYFIELD(r) Base Unit that also now includes a MAYFIELD(r) Swivel
Adaptor. The Base Unit is constructed with improved rigidity and strength, all
while retaining the highly versatile and maneuverable features for the benefit
of optimal patient positioning. The Base Unit is now equipped with an improved
locking handle for easier opening and closing, along with a locking latch for
improved safety. No tools are required for the adjustment of the locking
handle or for fitting the base unit to the OR table. A MAYFIELD(r) Tri-Star
Swivel Adaptor is available for image-guided surgery procedures when ancillary
components are required.
The MAYFIELD(r) cranial stabilization product line was started by world renowned
neurosurgeon, Dr. Frank H. Mayfield, over 40 years ago. MAYFIELD(r) cranial
stabilization systems are used in brain procedures, including treatment of head
trauma injuries, pediatric disorders such as hydrocephalus, and biopsies and
cancer removal.
The new MAYFIELD(r) Composite Series products are sold by Integra's Europe,
Middle East and Africa neurosurgery sales organization.
Integra LifeSciences, a world leader in medical devices, is dedicated to
limiting uncertainty for surgeons, so they can concentrate on providing the
best patient care. Integra offers innovative solutions in orthopedics,
neurosurgery, spine, reconstructive and general surgery. For more information,
please visit www.integralife.eu
This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning the products and
services provided by Integra. Such forward looking statements involve risks
and uncertainties that could cause actual results to differ materially from
predicted or expected results. Among other things, the willingness of surgical
professionals to use Integra products may affect the prospects for their use in
surgical procedures. In addition, the economic, competitive, governmental,
technological and other factors, identified under the heading 'Risk Factors'
included in Item IA of Integra's Annual Report on Form 10-K for the year ended
December 31, 2011 and information contained in subsequent filings with the
Securities and Exchange Commission could affect actual results.
MAYFIELD is a registered trademark of SM USA Inc. and is used by Integra under
license.
CONTACT: United States:
Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella(at)integralife.com
EMEA
Integra LifeSciences Holdings Corporation
Marie-Anne Girel
Manager, Communications
Europe, Middle East and Africa
marie-anne.girel(at)integralife.com
News Source: NASDAQ OMX
25.10.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Integra LifeSciences Holdings Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US4579852082
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 196072
Anzahl Zeichen: 4476
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 268 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Integra LifeSciences Holdings Corporation press release"
steht unter der journalistisch-redaktionellen Verantwortung von
Integra LifeSciences Holdings Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
